Asthma Therapeutics in Asia-Pacific Market Analysis and Treatment, 2021: Hexa Reports
- Submitted by: HexaReport
- Views: 63
- Category: Other
- Date Submitted: 05/19/2016 11:08 PM
- Pages: 5
- Report this Essay
Hexa Reports
Market Research Reports and Insightful Company Profiles
Asthma Therapeutics in Asia-Pacific Market Size, Share,
Growth, Treatment, Analysis, Symptoms, Emerging Trends
and Opportunities to 2021
Asthma Therapeutics in Asia-Pacific Markets to 2021 - High Prevalence and Launch of Late-Stage
Biologics will Drive the Market in Spite of Affordability Concerns
Summary
Asthma is a common chronic inflammatory disease of the airways, characterized by recurrent attacks of
breathlessness and wheezing, which vary in frequency and severity from patient to patient. The exact
causes of asthma are currently unknown, and may be the result of a combination of factors, although
two major factors thought to be involved are environmental exposure and host factors, particularly
genes.
Browse Detail Report With TOC @
http://www.hexareports.com/report/asthma-therapeutics-in-asia-pacific-markets/details
Asthma treatment can be classed as either a long-term control medication, aimed at controlling
persistent asthma, or a quick-relief medication, for the relief of exacerbations and acute symptoms.
Long-term control medication includes Inhaled Corticosteroids (ICS), immunomodulators, leukotriene
modifiers, cromolyn sodium, nedocromil and methylxanthines.
Hexa Reports
Market Research Reports and Insightful Company Profiles
In addition, Long-Acting Beta-Adrenoceptor Agonists (LABAs) can be used in combination with ICSs
– but not as monotherapies – for moderate or severe persistent asthma. Currently, only
one biologic – Xolair (omalizumab) – is approved as an add-on therapy for the treatment
of allergic asthma in the Asia-Pacific region. Nevertheless, significant unmet need remains for the
treatment of severe eosinophilic asthma.
Request A Sample copy of This Report @ http://www.hexareports.com/sample/105553
Scope
The current asthma market in the Asia-Pacific region contains novel products, including Xolair, a
recombinant humanized monoclonal anti-IgE...
Market Research Reports and Insightful Company Profiles
Asthma Therapeutics in Asia-Pacific Market Size, Share,
Growth, Treatment, Analysis, Symptoms, Emerging Trends
and Opportunities to 2021
Asthma Therapeutics in Asia-Pacific Markets to 2021 - High Prevalence and Launch of Late-Stage
Biologics will Drive the Market in Spite of Affordability Concerns
Summary
Asthma is a common chronic inflammatory disease of the airways, characterized by recurrent attacks of
breathlessness and wheezing, which vary in frequency and severity from patient to patient. The exact
causes of asthma are currently unknown, and may be the result of a combination of factors, although
two major factors thought to be involved are environmental exposure and host factors, particularly
genes.
Browse Detail Report With TOC @
http://www.hexareports.com/report/asthma-therapeutics-in-asia-pacific-markets/details
Asthma treatment can be classed as either a long-term control medication, aimed at controlling
persistent asthma, or a quick-relief medication, for the relief of exacerbations and acute symptoms.
Long-term control medication includes Inhaled Corticosteroids (ICS), immunomodulators, leukotriene
modifiers, cromolyn sodium, nedocromil and methylxanthines.
Hexa Reports
Market Research Reports and Insightful Company Profiles
In addition, Long-Acting Beta-Adrenoceptor Agonists (LABAs) can be used in combination with ICSs
– but not as monotherapies – for moderate or severe persistent asthma. Currently, only
one biologic – Xolair (omalizumab) – is approved as an add-on therapy for the treatment
of allergic asthma in the Asia-Pacific region. Nevertheless, significant unmet need remains for the
treatment of severe eosinophilic asthma.
Request A Sample copy of This Report @ http://www.hexareports.com/sample/105553
Scope
The current asthma market in the Asia-Pacific region contains novel products, including Xolair, a
recombinant humanized monoclonal anti-IgE...